Zai Lab Limited (NASDAQ:ZLAB – Get Rating)’s stock price was up 11.1% during mid-day trading on Tuesday . The stock traded as high as $31.37 and last traded at $30.80. Approximately 11,917 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 787,826 shares. The stock had previously closed at $27.73.
Several equities research analysts recently issued reports on ZLAB shares. Citigroup cut their target price on shares of Zai Lab from $198.00 to $193.00 in a research note on Thursday, May 12th. SVB Leerink cut their price objective on shares of Zai Lab from $102.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Finally, JPMorgan Chase & Co. cut their price objective on shares of Zai Lab from $136.00 to $112.00 and set an “overweight” rating for the company in a research report on Monday, April 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Zai Lab presently has an average rating of “Buy” and an average target price of $117.50.
The company’s fifty day moving average price is $33.96 and its 200 day moving average price is $45.70. The company has a market capitalization of $2.97 billion, a P/E ratio of -5.25 and a beta of 1.22.
About Zai Lab (NASDAQ:ZLAB)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.
- Get a free copy of the StockNews.com research report on Zai Lab (ZLAB)
- Should Silver Stocks Be A Part Of Your Portfolio?
- ABM Industries, A Clean Play For Dirty Economic Times
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
- Two Defensive Stocks To Get Aggressive With
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.